Combined COVID-19-related chronic hypoxemia and lack of screening as a double challenge for the management of asymptomatic invasive lung adenocarcinoma
DOI:
https://doi.org/10.15584/ejcem.2025.1.8Keywords:
chest CT, COVID-19, hypoxemia, LADC, screeningAbstract
Introduction and aim. Lung adenocarcinoma (LADC) is the most diagnosed histological subtype of lung cancer and the lead ing cause of cancer death in men in Algeria. Defining the circumstances that preceded the diagnosis improves the manage ment options and reduces its incidence. However, data for this critical period are lacking. We report the case of a patient whose onset of severe COVID-19 and the incidental finding of an undefined LADC overlapped and delayed care of the malignancy.
Case description. We present the case of a 65-year-old man, with invasive LADC discovered during a chest CT scan performed for suspected severe COVID-19. We describe the diagnostic methods and the patient. Histological examination by biopsy re quired to confirm diagnosis could not be performed due to chronic hypoxemia in the patient, which prevented the complete pathological diagnosis and staging of the disease.
Conclusion. Given the prevalence and aggressiveness of LADC in men in Algeria, our study underscores the critical need to develop screening programs, aimed at identifying the disease in asymptomatic patients, in asymptomatic patients that could significantly improve the chances of successful treatment. This is particularly important because LADC patients often develop serious pathologies that can limit their treatment options. COVID-19 serves as a stark example of such limiting interference, further highlighting the importance of early detection in the management of LADC.
Downloads
References
Myers DJ, Wallen JM. Lung Adenocarcinoma. StatPearls. 2024.
Xi J, Yin J, Liang J, et al. Prognostic Impact of Radiological Consolidation Tumor Ratio in Clinical Stage IA Pulmonary Ground Glass Opacities. Front Oncol. 2021;11:616149. doi: 10.3389/fonc.2021.616149
Weng CF, Huang CJ, Huang SH, et al. New International Association for the Study of Lung Cancer (IASLC) Pathology Committee Grading System for the Prognostic Outcome of Advanced Lung Adenocarcinoma. Cancers (Basel). 2020;12(11):3426. doi: 10.3390/cancers12113426
Casal-Mourino A, Ruano-Ravina A, Lorenzo-Gonzalez M, et al. Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. Transl Lung Cancer Res. 2021;10(1):506-518. doi: 10.21037/tlcr.2020.03.40
Quadrelli S, Lyons G, Colt H, Chimondeguy D, Buero A. Clinical characteristics and prognosis of incidentally detected lung cancers. Int J Surg Oncol. 2015;2015:287604. doi: 10.1155/2015/287604
Kocher F, Lunger F, Seeber A, et al. Incidental Diagnosis of Asymptomatic Non-Small-Cell Lung Cancer: A Registry-Based Analysis. Clin Lung Cancer. 2016;17(1):62-67. doi: 10.1016/j.cllc.2015.08.006
Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069. doi: 10.1001/jama.2020.1585
Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733. doi: 10.1056/NEJMoa2001017
Sohrabi C, Alsafi Z, O’Neill N, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020;76:71-76. doi: 10.1016/j.ijsu.2020.02.034
Guillo E, Bedmar Gomez I, Dangeard S, et al. COVID-19 pneumonia: Diagnostic and prognostic role of CT based on a retrospective analysis of 214 consecutive patients from Paris, France. Eur J Radiol. 2020;131:109209. doi: 10.1016/j.ejrad.2020.109209
Iadevaia C, Perrotta F, Mazzeo G, et al. Incidental diagnosis of lung adenocarcinoma following coronavirus OC 43 severe pneumonia. Monaldi Arch Chest Dis. 2020;90(3) doi: 10.4081/monaldi.2020.1313
Wang P, Martel P, Hajjam ME, et al. Incidental diagnosis of lung cancer on chest CT scan performed for suspected or documented COVID-19 infection. Respir Med Res. 2024;85:101084. doi: 10.1016/j.resmer.2024.101084
Madan A, Siglin J, Khan A. Comprehensive review of implications of COVID-19 on clinical outcomes of cancer patients and management of solid tumors during the pandemic. Cancer Med. 2020;9(24):9205-9218. doi: 10.1002/cam4.3534
Zhang Y, Li J, Li ZK, et al. Impact of Coronavirus Disease 2019 on Clinical Characteristics in Patients With Lung Cancer: A Large Single-Centre Retrospective Study. Front Oncol. 2021;11:693002. doi: 10.3389/fonc.2021.693002
Mojsak D, Debczynski M, Kuklinska B, et al. Impact of COVID-19 in Patients with Lung Cancer: A Descriptive Analysis. Int J Environ Res Public Health. 2023;20(2)1583. doi: 10.3390/ijerph20021583
IARC. Cancer today. https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf. Accessed September 5, 2024.
Bekara MEA, Djebbar A, Sebaihia M, Bouzeghti MEA, Badaoui L. Bayesian spatio-temporal analysis of the incidence of lung cancer in the North West of Algeria, 2014-2020. Spat Spatiotemporal Epidemiol. 2023;45:100583. doi: 10.1016/j.sste.2023.100583
Benarba B, Meddah B, Hamdani H. Cancer incidence in North West Algeria (Mascara) 2000-2010: results from a population-based cancer registry. EXCLI J. 2014;13:709-723.
Lahmadi M, Beddar L, Ketit S, Makhbouche T, Laouar N, Filali T. Clinicopathological characteristics and prognosis of non-small cell lung cancer in Algeria: a single-center retrospective study. BMC Cancer. 2024;24(1):946. doi: 10.1186/s12885-024-12709-5
Adda Bounedjar MAM, Hassina Idir, and Nassiba Heba. General Oncology Care in Algeria. Cancer in the Arab World. Springer, 2022;2. doi: 10.1007/978-981-16-7945-2
Jazieh AR, Bounedjar A, Abdel-Razeq H, et al. Impact of COVID-19 on Management and Outcomes of Oncology Patients: Results of MENA COVID-19 and Cancer Registry (MCCR). J Immunother Precis Oncol. 2024;7(2):82-88. doi: 10.36401/JIPO-23-38
Bounedjar A, Benkali R, Badoui L, et al. Incidence of lung cancer in males and females in Algeria: The lung cancer registry in Algeria (LuCaReAl). Cancer Epidemiol. 2020;69:101799. doi: 10.1016/j.canep.2020.101799
Ketfi A, Zanoun N, Laouedj I, Gharnaout M, Fraga S. [Primary lung cancer and occupational exposure in a North African population]. Pan Afr Med J. 2020;37:120. doi: 10.11604/pamj.2020.37.120.21755
Belkacemi Y, Grellier N, Ghith S, et al. A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries. Eur J Cancer. 2020;135:130-146. doi: 10.1016/j.ejca.2020.05.015
Hamdi Cherif M, Serraino D, Mahnane A, et al. Time trends of cancer incidence in Setif, Algeria, 1986-2010: an observational study. BMC Cancer. 2014;14:637. doi: 10.1186/1471-2407-14-637
Hashmi HAS, Asif HM. Early Detection and Assessment of Covid-19. Front Med (Lausanne). 2020;7:311. doi: 10.3389/fmed.2020.00311
Schwartz M. A biomathematical approach to clinical tumor growth. Cancer. 1961;14:1272-1294. doi: 10.1002/1097-0142(196111/12)14:6<1272::aid-cncr2820140618>3.0.co;2-h
Lim W, Ridge CA, Nicholson AG, Mirsadraee S. The 8(th) lung cancer TNM classification and clinical staging system: review of the changes and clinical implications. Quant Imaging Med Surg. 2018;8(7):709-718. doi: 10.21037/qims.2018.08.02
Luo J, Rizvi H, Preeshagul IR, et al. COVID-19 in patients with lung cancer. Ann Oncol. 2020;31(10):1386-1396. doi: 10.1016/j.annonc.2020.06.007
Li K, Wu J, Wu F, et al. The Clinical and Chest CT Features Associated With Severe and Critical COVID-19 Pneumonia. Invest Radiol. 2020;55(6):327-331. doi: 10.1097/RLI.0000000000000672
Brumini I, Dodig D, Zuza I, et al. Validation of Diagnostic Accuracy and Disease Severity Correlation of Chest Computed Tomography Severity Scores in Patients with COVID-19 Pneumonia. Diagnostics (Basel). 2024;14(2):148. doi: 10.3390/diagnostics14020148
Ramdani H, Allali N, Chat L, El Haddad S. Covid-19 imaging: A narrative review. Ann Med Surg (Lond). 2021;69:102489. doi: 10.1016/j.amsu.2021.102489
Romero Starke K, Reissig D, Petereit-Haack G, Schmauder S, Nienhaus A, Seidler A. The isolated effect of age on the risk of COVID-19 severe outcomes: a systematic review with meta-analysis. BMJ Glob Health. 2021;6(12):e006434. doi: 10.1136/bmjgh-2021-006434
Zhang H, Ma S, Han T, et al. Association of smoking history with severe and critical outcomes in COVID-19 patients: A systemic review and meta-analysis. Eur J Integr Med. 2021;43:101313. doi: 10.1016/j.eujim.2021.101313
Onishi H, Yamamura O, Sakamaki I, Miyashita H, Iwasaki H. Can the Brinkman Index Predict the Need for Treatment in Patients With COVID-19? Asia Pac J Public Health. 2022;34(6-7):692-694. doi: 10.1177/10105395221113773
Gallus S, Scala M, Possenti I, et al. The role of smoking in COVID-19 progression: a comprehensive meta-analysis. Eur Respir Rev. 2023;32(167):220191. doi: 10.1183/16000617.0191-2022
Le VT, Ha QH, Tran MT, Le NT, Le VT, Le MK. Hyperglycemia in Severe and Critical COVID-19 Patients: Risk Factors and Outcomes. Cureus. 2022;14(8):e27611. Doi: 10.7759/cureus.27611
Feng Y, Ling Y, Bai T, et al. COVID-19 with Different Severities: A Multicenter Study of Clinical Features. Am J Respir Crit Care Med. 2020;201(11):1380-1388. doi: 10.1164/rccm.202002-0445OC
Lemos AEG, Silva GR, Gimba ERP, Matos ADR. Susceptibility of lung cancer patients to COVID-19: A review of the pandemic data from multiple nationalities. Thorac Cancer. 2021;12(20):2637-2647. doi: 10.1111/1759-7714.14067
Chen L, Liu Y, Wu J, et al. Lung adenocarcinoma patients have higher risk of SARS-CoV-2 infection. Aging (Albany NY). 2021;13(2):1620-1632. doi: 10.18632/aging.202375
Weerahandi H, Hochman KA, Simon E, et al. Post-Discharge Health Status and Symptoms in Patients with Severe COVID-19. J Gen Intern Med. 2021;36(3):738-745. doi: 10.1007/s11606-020-06338-4
Loerinc LB, Scheel AM, Evans ST, Shabto JM, O’Keefe GA, O’Keefe JB. Discharge characteristics and care transitions of hospitalized patients with COVID-19. Healthc (Amst). Mar 2021;9(1):100512. doi: 10.1016/j.hjdsi.2020.100512
Steinbeis F, Thibeault C, Doellinger F, et al. Severity of respiratory failure and computed chest tomography in acute COVID-19 correlates with pulmonary function and respiratory symptoms after infection with SARS-CoV-2: An observational longitudinal study over 12 months. Respir Med. 2022;191:106709. doi: 10.1016/j.rmed.2021.106709
Passaro A, Bestvina C, Velez Velez M, Garassino MC, Garon E, Peters S. Severity of COVID-19 in patients with lung cancer: evidence and challenges. J Immunother Cancer. 2021;9(3):e002266. doi: 10.1136/jitc-2020-002266
Malalasekera A, Nahm S, Blinman PL, Kao SC, Dhillon HM, Vardy JL. How long is too long? A scoping review of health system delays in lung cancer. Eur Respir Rev. 2018;27(149):180045. doi: 10.1183/16000617.0045-2018
Barata F, Fidalgo P, Figueiredo S, Tonin FS, Duarte-Ramos F. Limitations and perceived delays for diagnosis and staging of lung cancer in Portugal: A nationwide survey analysis. PLoS One. 2021;16(6):e0252529. doi: 10.1371/journal.pone.0252529
Cha MJ, Lee HY, Lee KS, et al. Micropapillary and solid subtypes of invasive lung adenocarcinoma: clinical predictors of histopathology and outcome. J Thorac Cardiovasc Surg. 2014;147(3):921-928. doi: 10.1016/j.jtcvs.2013.09.045
Xu L, Tavora F, Burke A. Histologic features associated with metastatic potential in invasive adenocarcinomas of the lung. Am J Surg Pathol. 2013;37(7):1100-1108. doi: 10.1097/PAS.0b013e31827fcf04
Chen PH, Chang KM, Tseng WC, Chen CH, Chao JI. Invasiveness and surgical timing evaluation by clinical features of ground-glass opacity nodules in lung cancers. Thorac Cancer. 2019;10(11):2133-2141. doi: 10.1111/1759-7714.13199
Henschke CI, Yankelevitz DF, Yip R, et al. Lung cancers diagnosed at annual CT screening: volume doubling times. Radiology. 2012;263(2):578-583. doi: 10.1148/radiol.12102489
Park S, Lee SM, Kim S, et al. Volume Doubling Times of Lung Adenocarcinomas: Correlation with Predominant Histologic Subtypes and Prognosis. Radiology. 2020;295(3):703-712. doi: 10.1148/radiol.2020191835
Mo Z, Yu L, Cao Z, Hu H, Luo S, Zhang S. Identification of a Hypoxia-Associated Signature for Lung Adenocarcinoma. Front Genet. 2020;11:647. doi: 10.3389/fgene.2020.00647
Gao L, Li GS, Li JD, et al. Identification of the susceptibility genes for COVID-19 in lung adenocarcinoma with global data and biological computation methods. Comput Struct Biotechnol J. 2021;19:6229-6239. doi: 10.1016/j.csbj.2021.11.026
Ullah MA, Alam S, Moin AT, Ahamed T, Shohael AM. Risk factors and actionable molecular signatures in COVID-19-associated lung adenocarcinoma and lung squamous cell carcinoma patients. Comput Biol Med. 2023;158:106855. doi: 10.1016/j.compbiomed.2023.106855
Serebrovska ZO, Chong EY, Serebrovska TV, Tumanovska LV, Xi L. Hypoxia, HIF-1alpha, and COVID-19: from pathogenic factors to potential therapeutic targets. Acta Pharmacol Sin. 2020;41(12):1539-1546. doi: 10.1038/s41401-020-00554-8
BTS. BTS recommendations to respiratory physicians for organising the care of patients with lung cancer. The Lung Cancer Working Party of the British Thoracic Society Standards of Care Committee. Thorax. 1998;53(1):1-8. doi: 10.1136/thx.53.suppl_1.s1
Malalasekera A, Blinman PL, Dhillon HM, et al. Times to Diagnosis and Treatment of Lung Cancer in New South Wales, Australia: A Multicenter, Medicare Data Linkage Study. J Oncol Pract. 2018;14(10):621-630. doi: 10.1200/JOP.18.00125
Hermens RP, Ouwens MM, Vonk-Okhuijsen SY, et al. Development of quality indicators for diagnosis and treatment of patients with non-small cell lung cancer: a first step toward implementing a multidisciplinary, evidence-based guideline. Lung Cancer. 2006;54(1):117-124. doi: 10.1016/j.lungcan.2006.07.001
Vidaver RM, Shershneva MB, Hetzel SJ, Holden TR, Campbell TC. Typical Time to Treatment of Patients With Lung Cancer in a Multisite, US-Based Study. J Oncol Pract. 2016;12(6):643-653. doi: 10.1200/JOP.2015.009605
O’Dowd EL, Tietzova I, Bartlett E, et al. ERS/ESTS/ESTRO/ESR/ESTI/EFOMP statement on management of incidental findings from low dose CT screening for lung cancer. Eur J Cardiothorac Surg. 2023;64(4)ezad302. Doi: 10.1093/ejcts/ezad302
Min JH, Lee HY, Lee KS, et al. Stepwise evolution from a focal pure pulmonary ground-glass opacity nodule into an invasive lung adenocarcinoma: an observation for more than 10 years. Lung Cancer. 2010;69(1):123-126. doi: 10.1016/j.lungcan.2010.04.022
Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2(8):706-714. doi: 10.1097/JTO.0b013e31812f3c1a
Rates ACSLCS. https://www.cancer.org/cancer/types/lung-cancer/detection-diagnosis-staging/survival-rates.html. Accessed September 16, 2024
Gareen IF, Gutman R, Sicks J, et al. Significant Incidental Findings in the National Lung Screening Trial. JAMA Intern Med. 2023;183(7):677-684. doi: 10.1001/jamainternmed.2023.1116
Dawson Q. NELSON trial: reduced lung-cancer mortality with volume CT screening. Lancet Respir Med. 2020;8(3):236. doi: 10.1016/S2213-2600(20)30059-X
Chen CY, Chen CH, Shen TC, et al. Lung cancer screening with low-dose computed tomography: Experiences from a tertiary hospital in Taiwan. J Formos Med Assoc. 2016;115(3):163-170. doi: 10.1016/j.jfma.2015.11.007
Pinsky PF. Lung cancer screening with low-dose CT: a world-wide view. Transl Lung Cancer Res. 2018;7(3):234-242. doi: 10.21037/tlcr.2018.05.12
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
